Vir Biotechnology to Provide Corporate Update and Report Third Quarter 2022 Financial Results on November 3, 2022
![Pharmaceuticals | Free Full-Text | Innovations and Patent Trends in the Development of USFDA Approved Protein Kinase Inhibitors in the Last Two Decades | HTML Pharmaceuticals | Free Full-Text | Innovations and Patent Trends in the Development of USFDA Approved Protein Kinase Inhibitors in the Last Two Decades | HTML](https://www.mdpi.com/pharmaceuticals/pharmaceuticals-14-00710/article_deploy/html/images/pharmaceuticals-14-00710-g017-550.jpg)
Pharmaceuticals | Free Full-Text | Innovations and Patent Trends in the Development of USFDA Approved Protein Kinase Inhibitors in the Last Two Decades | HTML
![After making $1M+ on illegal trades, former Puma Biotechnology executive gets prison term | Fierce Pharma After making $1M+ on illegal trades, former Puma Biotechnology executive gets prison term | Fierce Pharma](https://qtxasset.com/quartz/qcloud5/media/image/fiercepharma/1529589242/law-1063249_1920.jpg/law-1063249_1920.jpg?VersionId=NSVstLVrcPK1LB7Huolq3hfdevvb8FSs)
After making $1M+ on illegal trades, former Puma Biotechnology executive gets prison term | Fierce Pharma
![PUMA BIOTECHNOLOGY: Announces U.S. FDA Acceptance of Supplemental New Drug Application for Neratinib to Treat HER2-Positive Metastatic Breast Cancer | FDA Health News PUMA BIOTECHNOLOGY: Announces U.S. FDA Acceptance of Supplemental New Drug Application for Neratinib to Treat HER2-Positive Metastatic Breast Cancer | FDA Health News](https://s3.amazonaws.com/jnswire/jns-media/f0/6a/2277344/Neratinib.png)
PUMA BIOTECHNOLOGY: Announces U.S. FDA Acceptance of Supplemental New Drug Application for Neratinib to Treat HER2-Positive Metastatic Breast Cancer | FDA Health News
![Predicting Solubility of Newly-Approved Drugs (2016–2020) with a Simple ABSOLV and GSE(Flexible-Acceptor) Consensus Model Outperforming Random Forest Regression | SpringerLink Predicting Solubility of Newly-Approved Drugs (2016–2020) with a Simple ABSOLV and GSE(Flexible-Acceptor) Consensus Model Outperforming Random Forest Regression | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs10953-022-01141-7/MediaObjects/10953_2022_1141_Fig3_HTML.png)
Predicting Solubility of Newly-Approved Drugs (2016–2020) with a Simple ABSOLV and GSE(Flexible-Acceptor) Consensus Model Outperforming Random Forest Regression | SpringerLink
![Cancer hopeful neratinib plagued by diarrhea, analysis shows, but Puma cites a solution | Fierce Pharma Cancer hopeful neratinib plagued by diarrhea, analysis shows, but Puma cites a solution | Fierce Pharma](https://qtxasset.com/cdn-cgi/image/w=384,h=216,f=auto,fit=crop,g=0.5x0.5/https://qtxasset.com/quartz/qcloud5/media/image/2016-09/medicin15.jpg?VersionId=3CogD4YQi.2znGgf99ntdmU4af1X0DuG)
Cancer hopeful neratinib plagued by diarrhea, analysis shows, but Puma cites a solution | Fierce Pharma
![Celcuity Announces Clinical Trial Collaboration with Massachusetts General Hospital and Puma Biotechnology Celcuity Announces Clinical Trial Collaboration with Massachusetts General Hospital and Puma Biotechnology](https://storage.googleapis.com/accesswire/logos/subaccounts/18463.jpg?v=0)